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Abstract: Hepatocellular carcinoma (HCC) is the fifth most common type of cancer diagnosed and
the second leading cause of death worldwide. Despite advancement in current treatments for HCC,
the prognosis for this cancer is still unfavorable. This comprehensive review article focuses on all the
current technology that applies biomaterials to treat and study liver cancer, thus showing the versatility
of biomaterials to be used as smart tools in this complex pathologic scenario. Specifically, after
introducing the liver anatomy and pathology by focusing on the available treatments for HCC, this
review summarizes the current biomaterial-based approaches for systemic delivery and implantable
tools for locally administrating bioactive factors and provides a comprehensive discussion of the
specific therapies and targeting agents to efficiently deliver those factors. This review also highlights
the novel application of biomaterials to study HCC, which includes hydrogels and scaffolds to tissue
engineer 3D in vitro models representative of the tumor environment. Such models will serve to
better understand the tumor biology and investigate new therapies for HCC. Special focus is given to
innovative approaches, e.g., combined delivery therapies, and to alternative approaches—e.g., cell
capture—as promising future trends in the application of biomaterials to treat HCC.
Keywords: biomaterials; hepatocellular carcinoma; 3D models; nanoparticles; microparticles;
immunotherapy; scaffolds

1. Introduction
Biomaterials have recently become a powerful tool for the treatment and study of tumors,
including liver cancer. The peculiarity of using biomaterials for cancer relies on the variety and
versatility of their properties, which allow size, surface charge and chemistry, shape, morphology, and
physiochemical properties, to be tuned according to target applications. Being processable from the
nano- to the macro-scale, biomaterials-based technologies can tremendously support the therapies
available for liver cancer and the comprehension of this disease by enabling advanced in vitro models.
In this review, we provide a comprehensive overview of the biomaterial-based approaches released
or under development for liver cancer. Starting from a framework of the liver microenvironment,
including normal and neoplastic tissue, and the current treatment methods available for hepatic tumors,
this review focuses on highlighting the biomaterials-based therapies that have been developed for liver
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Figure 1. Schematic of the structure of liver lobule.
Figure 1. Schematic of the structure of liver lobule.
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Cancers 2019, 11, 2026

4 of 41

3. Liver Neoplasia

Cancers 2020, 12, x FOR PEER REVIEW

4 of 44

Liver tumors are a heterogeneous neoplasia with a great clinical relevance due to morbidity and
3. Liver
Neoplasia
mortality
rates.
Hepatic neoplasms can be classified as: (1) primary tumors, when derived from the
liver parenchyma
such
hepatocellular
carcinoma
intrahepatic
cholangiocarcinoma
Liver tumors
areas
a heterogeneous
neoplasia
with(HCC),
a great clinical
relevance
due to morbidity and(iCC),
mortality rates.
Hepatic
neoplasms
can be classified
as: (1)
primary
tumors,
when derived
from
the
fibrolamellar
carcinoma
and
hepatoblastoma
(an early
liver
tumor
in children);
and (2)
secondary
liverwhen
parenchyma
hepatocellular
(HCC), (e.g.,
intrahepatic
cholangiocarcinoma
(iCC),breast,
tumors,
derivedsuch
fromasmetastatic
cellscarcinoma
of other tumors
colorectal,
pancreas, stomach,
carcinoma
and hepatoblastoma (an early liver tumor in children); and (2) secondary
ovaryfibrolamellar
cancers, and
so on) [16].
tumors,
when
derived
from
metastatic
cellsmost
of other
tumors
(e.g.,
colorectal, increasing
pancreas, stomach,
Among all these neoplasms,
HCC is the
common
and
a constantly
incidence in
breast, ovary cancers, and so on) [16].
the last decades. HCC has become the fifth most common cancer diagnosed and the second leading
Among all these neoplasms, HCC is the most common and a constantly increasing incidence in
cause of death in the world, with prevalent mortality rates in men [16].
the last decades. HCC has become the fifth most common cancer diagnosed and the second leading
The most
frequent
factors
HCC development
chronic
cause
of death
in the risk
world,
with for
prevalent
mortality rates are
in men
[16]. infections with hepatitis B virus
(HBV) and
virus
(HCV),
even
though
in the
last years
have
becomewith
lesshepatitis
significant
among
TheCmost
frequent
risk
factors
for HCC
development
arethey
chronic
infections
B virus
young
people
The
vaccination
campaigns
to prevent
HBV,
pharmacological
treatments,
(HBV)
and [17].
C virus
(HCV),
even though
in the last
years they
havenew
become
less significant among
peopleand
[17].a The
vaccination
campaigns to
HBV, new
pharmacological
earlyyoung
diagnosis,
more
diffuse knowledge
onprevent
the possible
transmission
routestreatments,
of these virus,
early
diagnosis,
and
a
more
diffuse
knowledge
on
the
possible
transmission
routes
of
these
virus, have
have led to a decrease of chronic viral liver diseases. Nevertheless, other risk factors for HCC
have
led
to
a
decrease
of
chronic
viral
liver
diseases.
Nevertheless,
other
risk
factors
for
HCC
have
demonstrated a growing incidence, such as diabetes, obesity, alcohol and tobacco consumption,
demonstrated
a
growing
incidence,
such
as
diabetes,
obesity,
alcohol
and
tobacco
consumption,
metabolic disease, heritable syndromes, and aflatoxins. Such factors are indeed prevalent in some
metabolic disease, heritable syndromes, and aflatoxins. Such factors are indeed prevalent in some
areas of the world—such as Europe, and North and Latin America—where HCC shows an unfavorable
areas of the world—such as Europe, and North and Latin America—where HCC shows an
growing
trend. Differently, in East Asia, where HCC mainly occurs from viral infections or aflatoxins
unfavorable growing trend. Differently, in East Asia, where HCC mainly occurs from viral infections
exposure,
a decrease
or steady
trendorhas
beentrend
identified
[17].
or aflatoxins
exposure,
a decrease
steady
has been
identified [17].
3.1. Diagnosis
3.1. Diagnosis
Thanks
to the
advanced
imaging
surveillanceguidelines
guidelines
follow
up programs
Thanks
to the
advanced
imagingtechniques,
techniques, surveillance
andand
follow
up programs
havehave
beenbeen
established
in different
countries
liverdisease
diseaseofofany
any
etiologies, to
established
in different
countriesfor
forpatients
patientswith
with chronic
chronic liver
etiologies,
to perform
tumor diagnosis
and staging.
Ultrasound
the primary
screening
method
to
perform
tumor diagnosis
and staging.
Ultrasound
is theisprimary
screening
method
usedused
to evaluate
identify
hepaticOther
lesions.
Other imaging
techniques,
the contrastliver evaluate
integrityliver
andintegrity
identifyand
hepatic
lesions.
imaging
techniques,
such assuch
theas
contrast-enhanced
enhanced
computer (CT)
tomography
(CT) or
magnetic imaging
resonance(MRI),
imaging
are employed
to the
computer
tomography
or magnetic
resonance
are(MRI),
employed
to improve
improve the diagnosis and describe the staging of the tumor [18]. These radiological methods
diagnosis and describe the staging of the tumor [18]. These radiological methods established criteria
established criteria which allow liver lesions and staging systems set up for HCC, such as the
which allow liver lesions and staging systems set up for HCC, such as the Barcelona-Clinic Liver Cancer
Barcelona-Clinic Liver Cancer (BCLC) (Figure 3), to be categorized, thus helping the correct
(BCLC)
(Figure evaluation
3), to be categorized,
thus helping
theimaging
correct diagnostic
[19].
Nevertheless,
diagnostic
[19]. Nevertheless,
atypical
appearanceevaluation
may require
histological
atypical
imaging
appearance
may
require
histological
analysis.
analysis.

Figure
3. 3.Barcelona-Clinic
LiverCancer
Cancer(BCLC)
(BCLC)
criteria.
Figure
Barcelona-Clinic Liver
criteria.

The The
immunohistochemical
antigens,such
suchasasGlypican
Glypican
3, heat
shock
protein
immunohistochemicaldetection
detection of
of antigens,
3, heat
shock
protein
70, 70,
glutamine
synthetase
and
clathrin
usedtotoconfirm
confirm
the
diagnosis
for HCC.
Biopsy
glutamine
synthetase
and
clathrinheavy
heavychain,
chain, is used
the
diagnosis
for HCC.
Biopsy
can can
fail
to achieve
sufficient
sensitivityand
andspecificity
specificity due
errors
or differential
diagnosis
fail to
achieve
sufficient
sensitivity
duetotosampling
sampling
errors
or differential
diagnosis
misunderstanding
(e.g.,
between
early-stage
HCC
and
dysplastic
nodules)
[20].
Genomic
expression
misunderstanding (e.g., between early-stage HCC and dysplastic nodules) [20]. Genomic expression
profiles
extensively
described
for HCC,
by means
of new
biomolecular
technologies,
profiles
havehave
extensively
beenbeen
described
for HCC,
by means
of new
biomolecular
technologies,
namely,
namely, microarrays and next-generation sequences (NGS) and correlation between the expression
microarrays and next-generation sequences (NGS) and correlation between the expression of molecular
of molecular markers and pathological features, etiology, and clinical outcomes have been proposed
markers and pathological features, etiology, and clinical outcomes have been proposed [19]. Despite

Cancers 2019, 11, 2026

5 of 41

these developments, up to now there are no therapies targeting the major mutations of HCC and no
biomarkers able to predict the real response to a specific therapy [21]. To date, protocols of study and
evaluation of tumor staging have been drawn up, making it possible to identify the most appropriate
therapeutic intervention. BCLC criteria are the most used to establish HCC staging as they consider
the tumor characteristics, the performance status of the patient and the liver functional status; finally,
they suggest a potential treatment which can increase the patient’s benefit and survival. The staging
classification and the treatment schedule can be applied to the majority of HCC patients, although a
special consideration has to be warranted to patients with impaired liver function who are candidate
for liver transplantation [22]. Based on the staging of HCC, different treatments can be applied to treat
this disease.
3.2. Current Treatment Methods
3.2.1. Surgical Resection
This treatment has the best performance in patients in very early or early stages of the tumor
(BCLC 0-A), without cirrhosis and with variable tumor size, although the tumor extension is a poor
prognostic factor [23]. New algorithms for surgical strategies have been proposed to treat HCC patients
with BCLC stages B and C by considering the tumor burden, the functionality of the liver reserve and
the volume of the remnant liver. There are different scoring systems for estimating liver functional
reserve, including Child–Pugh–Turcotte (CPT), the model for end-stage liver disease (MELD), and the
aspartate transaminase-to-platelet ratio index (APRI). However, the predictive potential and the results
produced by their application are not homogeneous since they do not take into account the patient’s
performance status. Recently, the serum bilirubin/serum cholinesterase (BILCHE) scoring system has
successfully been applied for selecting patients who can undergo surgical resection with a low risk of
postoperative complications [24]. Currently, only a low percentage of well-selected patients can benefit
of surgical resection. Recurrences after this approach are unfortunately frequent due to microscopic
vascular invasion and tumor dissemination or de novo tumor formation. Adjuvant therapies applied
after surgical resection, such as internal radiation therapy or immunotherapy, have been shown to
reduce recurrence of tumors, thus prolonging the overall survival [25–27].
3.2.2. Liver Transplant
Live transplant is the gold standard treatment in patients with liver cirrhosis and with tumor
lesions that subside into Milan criteria (MC) (i.e., patients who have a single tumor mass greater than
5 cm, or up to three lesions of 3 cm each). MC have been proposed by Mazzaferro et al. in 1996 [28],
and were adopted globally to select patients for liver transplantation: their application has resulted
in a 75% patients with a 5-year overall survival rate and only a 15% patients with tumor recurrence.
Although these criteria have been considered too restrictive, it has been observed that tumors exceeding
the MC have a higher recurrence and an increased risk to develop different tumor type leading to a
poor prognosis against those that fulfill MC. Indeed, many studies proposing expanded criteria still
require additional validation (UCSF, UCLA) [23].
3.2.3. Ablation
Ablation procedure is performed by injection of ethanol inside the tumor or by intratumor
radiofrequency which produce a necrotic area of about 3 cm diameter. It is a standard of care for
patients classified as BCLC A or 0 with tumor size less than 2 cm who cannot undergo or are considered
not to benefit from a surgical. Recently, microwave ablation has been applied in patients with larger
tumors showing a higher capability of inducing necrosis than radiofrequency. However, these tumor
treatments and other emerging ablative methods have shown a great efficacy only in small-size tumors
and present the same recurrence rate as observed after surgical resection [23,29].
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3.2.4. Chemoembolization
Transarterial chemoembolization (TACE) is a non-surgical procedure that combines embolization
with local delivery of drugs; as such, it is preferentially applied in patients with high HCC staging
(i.e., BCLC stage B) [29]. This therapeutic treatment has also been applied using drug-eluting beads
which can release the chemotherapeutic agent in a controlled manner by concentrating the drug in
the tumor site and reducing its systemic circulation. As an alternative to the use of chemotherapeutic
agents, the use of radioactive isotopes (i.e., radioembolization; RE) such as Yttrium-90 has recently
been proposed. The advantage of RE compared to TACE is that the microspheres used for RE have
a smaller size than the particles used for drug-eluting, thus reducing ischemia to the tumor and the
live tissue [29]. The best survival benefits from this procedure have been obtained in patients with
preserved liver function and without vascular or extrahepatic invasion of the tumor.
3.2.5. Chemotherapy
For patients classified as BCLC D, with advanced progression of HCC and metastasis, systemic
chemotherapy is the only treatment that can be applied to try to prolong overall survival. In the
latest years, the first line therapy is the chemotherapy drug Sorafenib (Sor) which is a tyrosine kinase
inhibitor (TKI). This drug functions by blocking cell surface tyrosine kinase receptors (TKRs) and/or
intracellular serine/threonine kinases, thus resulting in anti-angiogenic and anti-proliferative properties.
Sor treatment determines an increase of the overall survival and a delay in the progression of the
pathology. Despite these benefits, Sor has different severe side effects, such as diarrhea, arterial
hypertension, and dermatological adverse events like hand-foot skin reaction (HFSR), which may
require to stop the treatment [1]. Due to the limited efficiency of this therapy, other single therapeutic
agents have been investigated and are under study in clinical trials. Among different anti-angiogenic
TKI investigated in phase III trials, Lenvatinib has been demonstrated to reach a comparable or even
better efficacy than Sor. It has been considered as the alternative first line therapy for HCC treatment.
Nevertheless, also Lenvatinib can cause many adverse effects as hypertension, diarrhea anorexia,
fatigue, and weight loss [30].
In patients who do not tolerate Sor, Regorafenib, a multi-kinase inhibitor of vascular endothelial
growth factor receptor 1-3 (VEGFR1-3), has been approved as a second line therapy for HCC, due to the
survival benefits observed. In addition to multi-kinase inhibitors, different researches are evaluating
molecules able to block the different molecular pathways underlining hepatocarcinogenesis, or agents
that target the epigenetic dysregulation described for HCC. Tivantinib, which selectively inhibits
c-MET and HGFR, Everolimus, an mTOR inhibitor, or molecules which selectively block VEGFRs,
such as Axitinib or Apatinib are a subject of study. It has been observed that a single targeted agent is
less efficient than combination of multiple molecules for treating of HCC [31]. Nevertheless, it has
been observed that the combination of Sor with either TKI, such as erlotinib [32], or mammalian target
of rapamycin (mTOR) inhibitor (i.e., everolimus) [33], did not improve Sor efficacy. Moreover, the
combined therapy of Sor with the MAPK/ERK inhibitor Refametinib showed an increase in patient
survival but also caused grade 3 and 4 adverse events [34].
Together with the development of new pharmacological agents, many cytotoxic agents as
doxorubicin (DOX), cisplastin, 5-fluorouracil, and epirubicin have been also used as systemic therapy
for HCC but they did not show high improvements in overall survival and their combination caused
different side effects like an increase of myelotoxicity or neurotoxicity, neutropenia compared to the
single agent administration. Furthermore, different studies have investigated the combination of
therapies of Sor with TACE or with these systemic agents. They reported that the administration of Sor
in combination with one or more inhibitors may improve the benefits for the patient, although toxicity
and adverse effects may increase accordingly [31].
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3.2.6. Immunotherapy
Immune therapy has recently been introduced to treat HCC. The immune-based approach relies
on the observation that tumor cells can survive by escaping the immune system when they express,
on their surface membrane, the programmed cell death ligand 1 (PDL-1), which is able to bind the
programmed death-1 (PD-1) receptor on activated T cells. The interaction between these ligands leads
to the inactivation of T cells and consequently to the tumor cells survival [21]. Nivolumab is a human
monoclonal antibody currently used for different metastatic tumors: it has the ability to bind to PD-1
receptor interfering with the PDL-1 interaction and thus restoring the immunocompetence of T cells
against cancer. Similarly, Tremelimumab is used to block the cytotoxic T-lymphocyte antigen (CTLA-4),
allowing T cells to continue tumor cell destruction [35]. Clinical trials are ongoing to evaluate the
efficiency of these immune therapies as alternative treatments for HCC and point out the possible
adverse effects of their application either as single therapies or in combination with TACE or other
therapeutic approaches.
Recently, it has been observed that immunotherapy induced adverse effects such as rush,
fatigue, pruritis, and diarrhea and the increase of aspartate aminotransferase/alanine aminotransferase
worsening liver functionality. Cardiovascular toxicities have been also observed during the treatment
with immune checkpoint inhibitors [36]. Furthermore, in some cases, immune cell infiltration and a
delayed antitumoral response was demonstrated leading to the so called pseudoprogression of the
tumor [37].
Another therapeutic approach under evaluation for HCC treatment is based on the use of viruses
able to induce tumor cell death by activating the immune system. Second generation oncolytic human
herpes simplex virus type-1 has been genetically engineered to express the granulocyte macrophage
colony stimulating factor. It has been observed that oncolytic viruses are efficient against different
tumors blocking their growth and progression [38]. The induction of anti-tumor immunity using
tumor-associated antigens (TAAs) as peptide vaccines is a key research field, also applied to HCC [39].
For example, glypican protein 3 (GPC3) has been used as a potential peptide vaccine for its ability to
induce the cytotoxic T lymphocyte (CTL) response [40]. Furthermore, GPC3-derived epitope peptide
conjugated to liposomes seemed to be able to induce CTLs to inhibit the growth of GPC3-expressing
tumor [41]. Immune targeting of multi-drug resistance protein 3 (MRP3) was suggested to induce CTL
response against HCC cells which overexpress this transporter [42] and C-35 peptide from HCV-core
protein was shown to induce a specific IgG1 response [43].
3.2.7. Gene Therapy
MicroRNA (miRNA) and small-interfering RNA (siRNA) have been studied as nucleic acid-based
therapeutic drugs: miRNAs are non-coding single-strand molecules which act at post-translational
level or silencing RNAs [44]; siRNAs are double-stranded RNAs with the capability of specifically
targeting for degradation at several sites of antisense strand mRNA, thus knocking down the expression
of a specific gene [45]. The application of miRNAs and siRNAs is limited by their off-target effects that
can induce silencing of healthy genes. Moreover, delivery of these nucleic acids has many obstacles
such as nuclease degradation and body filtration [46]. In HCC, as in many tumors, miRNA profile
is altered compared to that of healthy subjects, showing both upregulation and downregulation of
miRNAs [47]. Some of these miRNAs are considered new possible biomarkers (e.g., miRNA-21),
while some others are potent tumor suppressors, like miRNA-34a, miRNA-29, and miRNA-122,
as they are downregulated in HCC patients [48,49]. As demonstrated by Deng and coauthors in
2011, their restoration can inhibit tumorigenesis using nanoparticles loaded with Rubone, a natural
compound able to upregulate miRNA-34a [50].
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4. Biomaterials for Drug Delivery in Liver Cancer
Cancer including HCC is a complex and diverse disease, which presents many challenges to
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augmented its retention in the PEG-PLA NPs. By increasing the length of the PLA chain, the retention
and antitumor activity was increased, enabling a complete eradication of the tumors in mice.
PLGA NPs have been widely used for cancer therapy; however, groups are moving towards
using a combination of PLGA with other synthetic or natural polymers to create optimal drug delivery
vehicles by leveraging the benefits of the different polymers. PLGA is very versatile in its ability to
adjust drug release rates; on the other hand, other polymers may be able to more efficiently load the
drugs of interest. For example, PBAE which has piperidine rings that can better carry the PTX and
CA4 drugs investigated by Zhang et al. [57]. However, PBAE alone is not a suitable polymer for drug
delivery, as it has poor stability in blood and has high positive charges [62]. Thus, combination with
PLGA, as shown by Zhang et al., resulted in NPs with enhance stability and adjustable release kinetics
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4.1.3. Natural Polymers Particles
PLGA
NPs have been widely used for cancer therapy; however, groups are moving towards
Natural polymer, unlike synthetic polymers, are naturally available in the environment. Gelatin is
using
a
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of PLGA with other synthetic or natural polymers to create optimal drug
a widely used and biocompatible protein, obtained as denatured collagen, that can be degraded by
delivery
vehicles by leveraging the benefits of the different polymers. PLGA is very versatile in its
metal matrix protease-2 (MMP2), which is over-expressed in tumors [63,64]. Liu et al. used gelatin
ability to adjust drug release rates; on the other hand, other polymers may be able to more efficiently
NPs to deliver DOX-lactose [65]. The NPs were constructed by self-assembly followed by crosslinking
load the drugs of interest. For example, PBAE which has piperidine rings that can better
carry the
of the gelatin (Figure 7). In fact, unlike collagen, non-crosslinked gelatin is soluble at 37 ◦ C.
PTX and CA4 drugs investigated by Zhang et al. [57]. However, PBAE alone is not a suitable polymer
DOX-lactose molecules were then conjugated to the particles where lactose was utilized to target
for drug delivery, as it has poor stability in blood and has high positive charges [62]. Thus,
HCC cells. The tumor extracellular matrix MMP2 leads to the degradation of the NPs and release of
combination with PLGA, as shown by Zhang et al., resulted in NPs with enhance stability and
DOX. In addition, there was a pH-responsive disassociation of DOX and lactose in the tumor cells,
adjustable release kinetics due to the PLGA and better loading bioavailability due to the PBAE [57].
resulting in free drug inside the cells. This method reduced the systemic toxicity generally produced
by DOX while increasing tumor inhibition rates. Hanes et al. used gelatin and chondroitin-6-sulfate
4.1.3. Natural Polymers Particles

Natural polymer, unlike synthetic polymers, are naturally available in the environment. Gelatin
is a widely used and biocompatible protein, obtained as denatured collagen, that can be degraded by
metal matrix protease-2 (MMP2), which is over-expressed in tumors [63,64]. Liu et al. used gelatin
NPs to deliver DOX-lactose [65]. The NPs were constructed by self-assembly followed by crosslinking

PTX and CA4 drugs investigated by Zhang et al. [57]. However, PBAE alone is not a suitable polymer
for drug delivery, as it has poor stability in blood and has high positive charges [62]. Thus,
combination with PLGA, as shown by Zhang et al., resulted in NPs with enhance stability and
adjustable release kinetics due to the PLGA and better loading bioavailability due to the PBAE [57].
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Figure 7. Preparation of GNPs-DOX-Lac particles. Reprinted with permission from Elsevier, Liu et al.,
Nanomedicine: Nanotechnology, Biology and Medicine, 2018, [65].

Chitosan is a cationic polysaccharide which is manufactured commercially through partial
deacetylation of chitin [67]. Chitosan NPs (CNPs) are usually fabricated through cationic chitosan
ionotropic gelation with polyanion sodium tripolyphosphate. Qi et al. demonstrated that CNPs
not loaded with any drug have antitumor effect on HCC cells due to neutralization of cell surface
charge, decrease of mitochondrial membrane potential, and induction of lipid peroxidation [68].
CNPs cause death by disrupting the cell membrane, decreasing the negative surface charge and
mitochondrial membrane potential, inducing lipid peroxidation, disturbing the fatty acid composition
of the membrane and fragmenting DNA. Xu et al. further showed that CNPs inhibit tumor growth
through tumor angiogenesis impairment [67]. The vascular endothelial growth factor receptor 2
(VEGFR2) levels was decreased, resulting in blockage of VEGF-induced endothelial cell activation.
CNPs have also been used to deliver other molecules and drugs. For example, Bu et al. utilized these
particles to delivery trans-resveratrol [69], and Cheng et al. [70] utilized these particles for gene therapy.
Chitosan ability to induce cancer cell death by itself and act also as a drug delivery vehicle make it is a
very promising natural polymer for hepatic cancer treatment.
4.1.4. Metallic NPs
Metallic NPs such as iron, gold and silver have been used in different biomedical applications for
imaging and therapy. Magnetic iron NPs have the ability to be controlled by superparamagnetism,
allowing the regulation of their movement and concentration using an external magnetic
field [71]. Xue et al. utilized galactosylated-carboxymethyl chitosan-magnetic iron oxide NPs
(Gal-CMCS-Fe3 O4 -NPs) to deliver the tumor suppressor gene RASSF1A [72]. They were able to
improve the transfection efficiency of the particles by controlling the direction of travel of the super
paramagnetic iron oxide NPs. Kou et al. focused on ultrasmall superparamagnetic iron oxide (USPIO)
NPs conjugated with humanized SM5-1 antibody, which binds to HCC cells [73]. These particles can be
used as contrast agents for diagnosis by MRI. Gold NPs main accumulation site is in the liver, and thus,
it is a promising biomaterials for the treatment of liver cancer [74,75]. Gold NPs are usually capped with
either sodium citrate, polyamidoamine dendrimers (PAMAM), or L-aspartate to stabilize the particles
and their cellular uptake is usually mediated by clathrin dependent endocytosis. One advantage of
these microparticles are their anti-angiogenic properties by inhibiting endothelial and fibroblast cell
proliferation [76]. Tomuleasa et al. reported on gold NPs conjugated non-covalently with L-aspartate
and conventional chemotherapy drugs, cisplatin/DOX/capecitabin, to deliver this anti-tumor therapy
through endocytic uptake into the cells [77]. Ma et al. used gold NPs conjugated with the antibody
for SM5-1 which was stabilized using sodium nitrate [78]. Paino et al. [74] also studied gold NPs
which were capped with either sodium citrate or polyamidoamine dendrimers (PAMAM). Finally,
Xue et al. used gold NPs to deliver miRNA-375 [75]. Compared to other types of NPs, metallic NPs are
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promising for the treatment of hepatic cancer due to their ability to be controlled by an electromagnetic
field, their broad optical properties which make results in their ability to not only serve as a delivery
vehicle, but also as contrast agent for imaging.
4.1.5. Lipid-Based Particles
Liposomes are characterized by a lipid bilayer that is formed from self-assembly of amphipathic
phospholipids, resulting in an interior aqueous space. Gao et al. used DOTAP/Cholesterol liposome
conjugated with anti-EGFR to target HCC cells. These liposomes were used to deliver adriamycin and
ribonucleotide reductase M2 (RRM2) siRNA. Their results demonstrated that the targeting and dual
delivery of both drugs gave rise to enhanced therapeutic effects compared to non-targeted or single
drug liposomes. Wei et al. investigated liposomes made of soybean phosphatidylcholine/cholesterol
which was PEGylated to deliver DOX [79]. PEGylation is advantageous as it increases circulation
time and avoids rapid clearance by the reticuloendothelial system [80,81]. Lo et al. also applied
PEGylated liposomes to deliver DOX, but the exact construct is unknown [82]. Wang et al. used
immunoliposomes to delivery DOX [83]. They used commercially available Ls-DOX, but modified it
by adding 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[maleimide(polyethylene glycol)-2000]
(DSPE-PEG-Mal) conjugated with Metuximab. Wang et al. also used liposomes, but the construct was
not specified. The liposome was loaded with a triple fusion plasmid of monomeric red fluorescence
protein, renilla luciferase, and herpes simplex virus truncated thymidine kinase or DOX. In addition,
an anti-CD44 antibody was conjugated to the loaded liposome [84]. Unlike liposomes which have
lipid bilayer, micelles are a lipid monolayers. Abdelmoneem et al. utilized dual-functionalized
spray-dried casein micelles (CAS-MCs) for combined delivery of two phytochemicals; berberine (BRB)
and diosmin [85]. Bogorad et al. studied lipidoids, which are lipid-like molecules that are synthesized
from alkyl-amines and alkyl-acrylates to deliver siRNAs that knockdown all integrin subunits in
hepatocytes [86]. Besides liposomes and micelles, groups have also applied lipid NPs to deliver
bioactive factors. As an example, Xu et al. utilized targeted solid lipid NPs to deliver docetaxel.
The primary components of this NP were dioleoylphosphatidyl ethanolamine (DOPE) and egg yolk
phosphatidylcholine (ePC), which are both biodegradable and biocompatible [87]. Huang et al. also
investigated lipid NPs; however, their NPs consisted of 1,2-distearoyl-sn-glycero-3-phosphatidylcholine
(DSPC), 1,2-dimyristoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy (polyethylene glycol)-2000
(DMPE-PEG2000), cholesterol, and a cationic lipid (RL01) and they were aimed to deliver anti-miR-17.
Lipid-based NP ability to easily and spontaneously self-assemble in aqueous environments, from
chemical components/monomers that are designed optimally, into vast three-dimensional particles
make it promising vehicles for drug delivery.
4.1.6. Other Particles
There are many other types of particles that have been developed using diverse biomaterials to
be applied in the treatment of HCC. Among those, Wang et al. used hydroxyapatite NPs to delivery
selenium [88]. Hydroxyapatite material itself is able to induce cell death and, thus these NPs act as both
a drug delivery vehicle and anticancer agent for HCC [89,90]. Pullulan-based NPs were investigated
by both Zhang et al. [57] and Wang et al. [91]. Pullulan is a polysaccharide enabling advantages
as it exhibited pH-sensitive properties, thus allowing control release property. There are several
other materials that have been used for liver cancer therapy including lipid-coated calcium carbonate
NPs [92], galactosamine-conjugated albumin [93], polyisohexylcyanoacrylate [94], dendrimer NPs [95],
insulin multimethacrylate particles [96], and glass microspheres [97].
4.2. Local Delivery
Compared to systemic delivery, local delivery of therapeutics allows for the decrease of systemic
toxicity and increase bioavailability of the drug. By delivering drugs locally, the drug concentration at
the tumor environment can be maximize and non-target systemic exposure and organ toxicity can be
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minimized. Furthermore, local delivery can increase the efficacy of the drug by bypassing the harsh
environment and longer journey that the drug has to take to reach the targeted site of interest.
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2007 [99].
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5. Biomaterials for Bioactive Factor Delivery in Liver Cancer Therapy and Imaging
5.1. Chemotherapy
DOX, also known by one of its trade name Adriamycin, is one of the most common drugs used
in liver cancer therapy and in many biomaterial based therapies [58,65,77,79,82,83,93,96,108,109,111].
Besides DOX, taxel-based drugs, such as docetaxel and PTX, are often used in biomaterial based therapies
for HCC as well [57,59,87,98]. Liang et al. studied PTX loaded poly(γ-glutamic acid)-poly(lactide)
NPs to deliver chemotherapy for HCC [59]. PTX is primarily utilized for breast and ovarian cancers,
however, as shown by Liang et al., it can also effective in treating HCC [112,113]. Zhang et al. also
used PTX, but in combination with combretastatin A4, which will be discussed later in this review.
Although it is structurally similar, docetaxel has shown to be more effective than PTX [114]. Docetaxel
functions as an inhibitor of the depolymerization of microtubules. Xu et al. loaded docetaxel into
the solid lipid NPs [58]. 5-Fluorouracil (5-FU) is a chemotherapeutic drug that disrupts nucleoside
metabolism resulting in DNA and RNA disorders [115,116]. Ma et al. utilized this drug by conjugating
it to PLA NPs [56]. Tomuleasa et al. tested multiple different chemotherapeutic drugs by loading gold
NPs with cisplatin, capecitabine, and DOX.
5.2. Radiotherapy
Radiotherapy can be often used as adjuvant therapy for the prevention of the recurrence of cancer
and/or metastases after the surgical resection of the tumor. Wang et al. investigated non-degradable
glass microparticles to deliver phosphorus-32 for preventive regional radiotherapy [97]. As it decays,
this radioisotope emits high energy beta particles. Wang et al. demonstrated that the glass microspheres
implanted in the liver was able to significantly decrease recurrence after surgery.
5.3. Immunotherapy
Immunotherapy is a promising approach for cancer treatment as it has the ability to develop
long-term immunity to the tumor originally treated [117]. Microparticle systems have shown ability
to improve immune response. As an example, Hanes et al. used gelatin and chondroitin-6-sulfate
microspheres to deliver IL-2 for immunotherapy [66]. Previously, IL-2 has been used to treat melanomas
and renal cell carcinoma through systemic means, but it has shown to be toxic in high doses [118].
Genetically-engineered autologous cells are currently the gold standard for immunotherapy [118].
These particles developed by Hanes et al. are relatively easier to manufacture compared to these
cells, and thus present a promising approach for cancer immunotherapy. Ma et al. used SM5-1,
a monoclonal antibody, as immunotherapy because it binds to p230, a membrane protein overexpressed
in HCC [78]. This antibody was shown to impede tumor growth, induce apoptosis, and downregulate
tumor angiogenesis [73,119–121].
5.4. Natural Occurring Compounds
Natural occurring compounds are drugs that can be extracted from plants and animals.
Abdelmoneed delivered two phytochemicals extracted from plants; berberine (BRB) and diosmin (DSN)
using micelles [85]. Ni et al. delivered both curcumin- and 5-fluorouracil-loaded with biotin-/lactobionic
acid–modified PEG-PLGA-PEG (BLPP) copolymer NPs and saw synergistic anticancer effects (i.e.,
cytotoxicity) in vivo [60]. Curcumin is a polyphenol extracted from turmeric inducing anti-angiogenic,
antitumor, and anti-inflammatory physiological responses [122]. Bu et al. also focused on a naturally
occurring compound. They loaded trans-resveratrol (as a model drug), a natural plant compound,
into CNPs, demonstrating that NPs were more effective on cancer cells compared to trans-resveratrol
solution [69].
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5.5. Gene Therapy
Gene therapy is used to treat a disease by transferring a therapeutic nucleic acid (i.e., plasmid
DNA, siRNA, or microRNA) to introduce a new gene or restore, increase or halt gene expression of
a gene.
5.5.1. Plasmid DNA
Plasmid DNAs are double-stranded, closed, and circular vectors often used for gene delivery
due to recombination techniques that allow genes to be inserted into the plasmid. Xue et al. utilized
galactosylated-carboxymethyl chitosan-magnetic iron oxide (Gal-CMCS-Fe3 O4 ) to deliver the tumor
suppressor gene Ras Association Domain Family 1A (RASSF1A) [72], which plays a vital role in
apoptosis, cell-cycle regulation, and microtubule stability [123,124]. HCC are lacking RASSF1A
expression [125] and thus, the delivery of this plasmid in combination with intraperitoneal injection
of mitomycin and an external magnetic field resulted in smallest tumors compared to other groups
tested. The re-expression of the RASSF1A gene resulted in increased sensitivity of HCC cells to
the chemotherapy drug mitomycin [72]. Xu et al. also combined chemotherapy with gene delivery.
They designed a double layered microparticles loaded with the chemotherapy drug DOX in the core
and chitosan-DNA NPs containing the gene encoding the p53 tumor suppressor protein (chi-p53) in the
shell. The combined treatment with DOX and chi-p53 treatment demonstrated enhanced cytotoxicity
as compared to either DOX or chi-p53 treatments alone. The p53 gene is a gene that is often mutated in
HCC, mostly in the apoptosis pathway mediated by p53 [126]. Thus, p53 expression using plasmid
DNA could help fix the control of normal cell growth.
5.5.2. siRNAs
Small interfering RNAs (siRNAs) are noncoding sequences used to disrupt the effects of mRNAs.
Gao et al. combined the delivery of a chemotherapy agent, Adriamycin, and ribonucleotide reductase
M2 (RRM2) siRNA with liposome-polycation-DNA complex (LPD) conjugated with anti-EGFR
(epidermal growth factor receptor) [127]. RRM2 expression is higher in HCC than in non-HCC tissue
and thus RRM2 siRNA is a promising therapy for HCC. Adriamycin may induce upregulation of
RRM2 and thus, the combination of Adriamycin and RRM2 siRNA can result in combined therapeutic
effects. The combined therapy resulted in enhanced therapeutic effects (i.e., cytotoxicity, apoptosis, and
senescence-inducing activity) compared with single-drug loaded or non-targeted controls. Bogorad et al.
delivered siRNAs targeting all integrin subunits in hepatocytes [86]. Integrins play an important role
during development, regulating cell differentiation, proliferation, and survival. The knockdown of the
integrin receptors significantly retarded the progression of HCC.
5.5.3. miRNAs
MiRNAs are also noncoding RNAs that are around 22 nucleotide long that modulate mRNA
stability and expression. MiRNAs can target multiple mRNAs simultaneously, while siRNAs can target
only one at a time [128]. Zhou et al. studied the delivery of the let-7g tumor suppressor miRNA using
dendrimer NPs that mediate miRNA delivery to late-stage liver tumors with low hepatotoxicity [95].
Huang et al. delivered antimiR-17 with a lipid NP. MiR-17 is an oncogene, and ectopic expression with
miR-17-3p results in the development of HCC in a mouse model [129,130]. The suppression of this
oncogene through antimiR-17 delivery hindered the proliferation of HCC cells. Although a first-line
drug for HCC, Sor often induces resistance due to autophagy [92]. Thus, Zhao et al. investigated the
delivery of Sor in combination with miR-375, an inhibitor of autophagy with lipid-coated calcium
carbonate NPs. Xue et al. also delivered miR-375, but using gold NPs [75]. Finally, Che et al. delivered
miRNA-145 in combination with PTX from an electrospun PCL scaffold [123].

Cancers 2019, 11, 2026
Cancers 2020, 12, x FOR PEER REVIEW

16 of 41
16 of 44

5.6. Imaging
5.6.
Imaging
Imaging in
in cancer
cancer therapy
therapyisisvital
vitaltotoassess
assesstumor
tumorgrowth
growthand/or
and/or
ensure
and
track
delivery
Imaging
ensure
and
track
thethe
delivery
of
of treatments.
Wang
al. applied
liposomes
to deliver
a reporter
agentallowed
which
treatments.
Wang
et al.etapplied
liposomes
to deliver
a reporter
system system
imagingimaging
agent which
allowed
them to and
monitor
and evaluate
the efficiency
of targeting
tumor
triple
fusion
(TF)
them
to monitor
evaluate
the efficiency
of targeting
the tumorthe
[84].
The [84].
tripleThe
fusion
(TF)
plasmid,
plasmid,
consist
of
monomeric
red
fluorescence
protein
(RFP),
renilla
luciferase
(Rluc),
and
herpes
consist of monomeric red fluorescence protein (RFP), renilla luciferase (Rluc), and herpes simplex virus
simplex virus
truncated
thymidine
kinase
(HSV-ttk)
and
was used
to monitor
the
truncated
thymidine
kinase
(HSV-ttk)
reporter
genes reporter
and was genes
used to
monitor
the response
of the
response
of
the
tumor
to
DOX
delivered
using
the
same
liposome
system.
Bio-optical
tumor to DOX delivered using the same liposome system. Bio-optical bioluminescence imaging (BLI)
bioluminescence
imaging
was
usedbytoFluc
monitor
tumor growth
status by Fluc
and to
targeting
of
was
used to monitor
tumor(BLI)
growth
status
and targeting
of the liposomal
particles
the site by
the liposomal
Rluc
(Figure 9).particles to the site by Rluc (Figure 9).

Figure 9. Schematic of targeted liposomes for imaging and therapy of HCC. The HCC model was
developed
by in situ of
injection
of liposomes
DF (Fluc, GFP)
HepG2 cells
with theof
progression
or regression
of HCC
Figure 9. Schematic
targeted
for imaging
and therapy
HCC. (A) The
HCC model
was
bearing
tracked
by
Fluc
imaging
in
vivo.
The
targeting
of
CD44
conjugated
liposomes
can
be
tracked
developed by in situ injection of DF (Fluc, GFP) HepG2 cells with the progression or regression of
by
Rluc
imaging.
HCC
resulted
from
administration
of GCV
and DOX.
Reprintedcan
with
HCC
bearing
tracked
byregression
Fluc imaging
in vivo.
The
targeting of CD44
conjugated
liposomes
be
permission
fromimaging.
Elsevier, HCC
Wangregression
et al., Biomaterials,
tracked by Rluc
resulted 2012
from[84].
administration of GCV and DOX. Reprinted

with permission from Elsevier, Wang et al., Biomaterials, 2012 [84].

Besides being used as drug delivery vehicles, ultrasmall superparamagnetic iron oxide can be
employed as contract agent in MRI. Indeed, Kou et al. utilized these particles for diagnostic imaging of
Besides being used as drug delivery vehicles, ultrasmall superparamagnetic iron oxide can be
HCC [73].
employed as contract agent in MRI. Indeed, Kou et al. utilized these particles for diagnostic imaging
of Targeted
HCC [73].Delivery
6.
Systemic
delivery systems often result in the accumulation of drugs in the mononuclear phagocytic
6. Targeted
Delivery
system cells in the liver, spleen, and bone marrow [131], and increase in hematologic toxicities due to
Systemic delivery systems often result in the accumulation of drugs in the mononuclear
circulation time [132]. Targeting agents to tumor cell surface antigens or receptors allow biomaterials
phagocytic system cells in the liver, spleen, and bone marrow [131], and increase in hematologic
to effectively and efficiently deliver bioactive factors to the cells of interest while decreasing side effects
toxicities due to circulation time [132]. Targeting agents to tumor cell surface antigens or receptors
to non-targeted cells.
allow biomaterials to effectively and efficiently deliver bioactive factors to the cells of interest while
decreasing
side effects to non-targeted cells.
6.1.
Antibodies
Antibodies have evolved into tumor targeting agents for drug delivery. Gao et al. used NPs
6.1. Antibodies
conjugated with anti-epidermal growth factor receptor (EGFR) since HCC cells overexpress EGFR [127].
have
evolved
into tumordelivered
targeting
for drug delivery.
Gao et al. used NPs
TheyAntibodies
found that the
NPs
can be efficiently
to agents
EGFR-overexpressing
or moderately-expressing
conjugated
with
anti-epidermal
growth
factor
receptor
(EGFR)
since
HCC
cells
overexpress
EGFR
HCC cells, but not to the HCC cells with low levels of EGFR. Wang et al. selected anti-CD147
antibodies
[127].
They
found
that
the
NPs
can
be
efficiently
delivered
to
EGFR-overexpressing
or
moderatelyto target HCC cells [83]. CD147 is an important marker in the progression of HCC and thus, it is also
expressing
HCC cells,
not toofthe
HCC
cells
with
lowEPR
levels
of EGFR.
Wang etaggregated
al. selectedonantihighly
expressed
on thebut
surface
HCC
cells.
Due
to the
effect,
the liposomes
the
CD147
antibodies
to
target
HCC
cells
[83].
CD147
is
an
important
marker
in
the
progression
of HCC
tumor and then absorbed through ligand mediated internalization. Wang et al. used anti-CD44
as a
and thus, agent
it is also
highlycancer
expressed
the(CSCs)
surfacefor
of HCC
HCC therapies
cells. Due[84].
to theMa
EPR
effect,
the liposomes
targeting
to target
stemon
cells
et al.
employed
SM5-1,
aggregated
on
the
tumor
and
then
absorbed
through
ligand
mediated
internalization.
Wang
al.
a humanized mouse antibody that has a high binding affinity for a membrane protein, p230, aet230
used anti-CD44 as a targeting agent to target cancer stem cells (CSCs) for HCC therapies [84]. Ma et
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kDA membrane protein overexpressed in HCC cells, in PLA NPs [56]. Ma et al. also used gold NPs
conjugated with SM5-1. This antibody was also used by Kou et al. with ultrasmall superparamagnetic
iron oxide for diagnostic imaging. Besides being a targeting agent, SM5-1 has been proved to be able
to inhibit tumor cell growth or induce apoptosis [78].
6.2. Carbohydrate-Targeting Agents
Due to the prevalence of carbohydrate-binding receptors on hepatocytes, carbohydrate can also be
used as targeting agents for HCC. Xue et al. delivered RASSF1A gene using a dual targeting approach
through galactosylated-carboxymethyl chitosan-magnetic iron oxide NPs (Gal-CMCS-Fe3 O4 -NPs) [133].
The galactosylation targets the asialoglycoprotein receptors (ASGP-Rs), while an external magnetic
field improves the efficiency of the gene therapy, potentially by directing the NPs to the target site [20].
ASGP-Rs are highly expressed on HCC cells. Xu et al. also used a galactose moiety in the form of
galactosylated DOPE, which was conjugated using lactobionic acid, to target the HCC cells. The uptake
into the cell was controlled by ligand-receptor binding, and endocytosis was mediated by clathrin.
Liu et al. covalently conjugated a hydrophilic glucosyl-galactose disaccharide, lactose, to DOX in order
to target the ASGPRs [65]. Wei et al. investigated Lactoferrin (Lf) to target HCC cells as Lf is able
to bind to the ASGP-R as well [134,135]. Galactosamine is another target for the ASGP-R. Shen et al.
conjugated this target to albumin NPs and used it to delivery DOX [93,111]. Similarly, Liang et al.
delivered PTX using poly(γ-glutamic acid) and poly(lactide) NPs with galactosamine conjugation to
target the liver cancer cells which resulted in specific interaction with the hepatoma tumor in mice via
ligand-receptor binding. This targeted chemotherapy demonstrated enhanced reduction of the tumor
in comparison to the non-targeted NP-PTX therapy [59]. Zhang et al. [57] targeted the ASGP-Rs as
well. The pullulan polysaccharide backbone in their biomaterials bind naturally to ASGP-Rs as shown
in Figure 5 [136]. Ni et al. used a dual targeting approach to target HCC cells [60]. Poly(ethylene
glycol)-poly(lactic-co-glycolic acid)-poly(ethylene glycol) (BLPP) copolymer NPs were synthesized and
conjugated with biotin-/lactobionic acid for targeted delivery of curcumin- and 5-fluorouracil. Due to
the dual targeting, a higher cellular uptake was seen in HCC cells, and a lower residual accumulation
was seen in normal tissue in comparison to the single targeting and non-targeting NPs [60]. Similarly,
Abdelmoneem et al. used lactobionic acid and folic acid to target nanomicelles loaded with the
phytochemicals berberine (BRB) and diosmin (DSN) to HCC cells [85].
6.3. Peptide/Protein-Targeting Agents
Monoclonal antibody have shown clinical potential, however its associated with impaired tumor
penetration [82]. Therefore, peptide-targeting agents have been developed to overcome this. Lo et al.
identified SP94, as a peptide targeting agent specific for HCC [82]. This peptide was conjugated to
PEGylated liposome and used to deliver DOX. The peptide-targeting agent can decrease hematologic
toxicities by avoiding the reduction in the total WBCs. When administered in vivo, there was
significantly more SP94 accumulated at tumor sites than other organs. Bibby et al. delivered DOX with
a NPs with a core made out of insulin multi-methacrylate with a targeting peptide, cyclic RGD [96].
6.4. Enhanced Permeability and Retention Effect (EPR)
Several biomaterials themselves often result in the selective accumulation of these vehicles and
their payload into tumors instead of normal tissue due to the enhanced permeability and retention effect
(EPR) [137]. CNPs are a prime example of this [67,68]. Particle size plays a role in the accumulation of
particles in the liver. Smaller particles are more likely to be internalized and aggregate at the tumors
due to the enhanced permeability and retention effect (EPR) [138]. However, larger NPs (>200 nm)
are more likely to be recognized by monocytes and the reticuloendothelial system [139]. Particles
made with gold also acts as its own targeting agent for HCC as gold accumulates in the liver [75].
Tomuleasa et al. [77], Paino et al. [74], and Ma et al. [78] did not use gold as only the bioactive factor,
but also as the targeting agent. Instead of using the biomaterial as the targeting agent, Ma et al. also
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From an historic perspective, the first studies related to the development of 3D in vitro models for
liver aimed to create structures for tissue engineering and organ transplantation [144]. Subsequently,
these models were also used for the evaluation of the efficacy and cytotoxicity of drugs, as well as
for the study of cell metabolism and pathological phenomena. Initially, the cells grown on these
3D supports were primary hepatocytes from rat or, most rarely, isolated from a patient. Indeed,
the difficulty in isolating human cells and the poor survival capacity of primary liver cells in culture
have led researchers to use cell lines derived from hepatocellular carcinoma (HCC), such as HepG2,
HepaRG, Huh7, and others [145]. The behavior of these lines appeared to be very similar to that
of primary cells with respect to the morphological aspect (e.g., cellular polarity), the synthesis of
molecules such as albumin and urea, the activity of detoxification enzymes, and the formation of
similar structures in the biliary canaliculi. Moreover, the 3D culture of these cell lines in the form
of spheroids has also been applied in researches aimed to obtain more detailed information on the
molecular mechanisms of liver tumor development and for the evaluation of the pharmacological
response to new anticancer drugs [144]. More recently, spheroids have evolved into organoids, which
are obtained by inducing the aggregation of multiple cell types (e.g., endothelial, mesenchymal, hepatic)
into macroscale (millimeter size) constructs acting as functional units [146]. Organoids have also been
derived from liver cancers [147]. However, due to their compactness, these organoids are usually vital
only for a limited timeframe in vitro. To have longer usable time points, scientists therefore use to
disaggregate and reform the organoids over time, like cells in culture.
The great advantage of biomaterial-based scaffolds over spheroids and organoids is multifold:
(1) allows for a better tissue biomimicry by providing a preliminary artificial extracellular matrix (ECM)
on which the cells can grow and assemble in a natural fashion, (2) provides mechanical and architectural
cues to which the cells can respond with a more reliable function, (3) can impart chemical signals thanks
to the chosen biomaterial and/or biomolecules, (4) permits cell survival for long times thanks to its
porosity, and (5) enables the generation of complex multicellular constructs in which diffusion gradients
can be consistent to cell viability and function [142]. For the development of 3D culture models of
HCC, both natural and synthetic materials have been used to obtain biodegradable and biocompatible
scaffolds with a porosity suitable for cell proliferation and microvasculature formation and infiltration.
The first scaffolds used in this research area have been produced starting from the (co)polymers
approved by FDA for biomedical applications, namely, polyglycolic acid (PGA), PLLA, PLGA, PCL,
and some others [148,149]. These biomaterials were processed into porous scaffolds prepared via
different techniques, including rapid prototyping and solvent evaporation combined with particle
elimination and cultured with hepatocytes for liver regeneration [150]. Only more than a decade later,
the concept of tissue engineering, which is inherently based on the use of biomaterial-scaffolds, has
been transferred to cancer research [151–154].
7.2. Hydrogel-Aided Spheroids for HCC
Spheroids are artefacts obtained in cell culture leading to compact cellular microspheres with a
broad size range (20–1000 µm) which have become largely used in cancer research [142,155]. In order
to improve the reliability of the results obtained with the spheroid model, many 3D cultures of liver
tumor cells are availing themselves of hydrogels based on collagen, alginate or gelatin, containing
molecules or growth factors immobilized in the structure via different chemical processes, even though
also synthetic hydrogels are recently gaining attention for their peculiar properties, such as stimuli
responsiveness [143,156–161]. Within these hydrogel structures, spheroidal masses or cell aggregates
are formed under non-adherence conditions, in which the ECM-cell interactions are very narrow and
grant for a better communication of intracellular transduction signals. Inherently, spheroids can only
partially mimic the tumor microenvironment (TME) in terms of ECM secretion, interaction between
cancer cells, diffusion gradients therefore increased resistance to treatments, whereas they lack of other
TME features, including phenotype diversity and tissue architecture [155,162]. Moreover, difficulties
in controlling spheroid size and obtaining consistent outcomes from assays have been reported,
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Figure 11. (A) Fabrication of a redox-degradable hydrogel by using horseradish peroxidase (HRP)
Figure 11. (A) Fabrication of a redox-degradable hydrogel by using horseradish peroxidase (HRP)
catalysis: self-oxidation of a thiolated polymer generating hydrogen peroxide, hydrogelation (dashed
catalysis: self-oxidation of a thiolated polymer generating hydrogen peroxide, hydrogelation (dashed
arrows), HRP-mediated phenoxyradical formation promoting disulfide bond between the thiolated
arrows), HRP-mediated phenoxyradical formation promoting disulfide bond between the thiolated
polymers (solid arrows). (B) Schematic of the fabrication and the recovery of cellular spheroids using
polymers (solid arrows). (B) Schematic of the fabrication and the recovery of cellular spheroids using
redox-responsive hydrogels: encapsulation of target cells, spheroid formation by cell proliferation,
redox-responsive hydrogels: encapsulation of target cells, spheroid formation by cell proliferation,
recovery of the spheroids by degrading the scaffolds under reductive conditions. Reprinted with
recovery of the spheroids by degrading the scaffolds under reductive conditions. Reprinted with
permission from Wiley, Moriyama et al., Biotechnol. J., 2016 [159].
permission from Wiley, Moriyama et al., Biotechnol. J., 2016 [159].

Another study has reported on the use of a temperature responsive hydrogel based on
Another study has reported on the use of a temperature responsive hydrogel based on poly(Npoly(N-isopropylacrylamide) (pNIPAAm)-co-gelatin for spheroid formation, in which the hepatoma
isopropylacrylamide) (pNIPAAm)-co-gelatin for spheroid formation, in which the hepatoma cell line
cell line Hepa/8F5 derived from a genetically engineered mouse model showed higher function with
Hepa/8F5 derived from a genetically engineered mouse model showed higher function with respect
respect to the 2D cell counterpart, according to albumin synthesis and other metabolic activities [160].
to the 2D cell counterpart, according to albumin synthesis and other metabolic activities [160]. In
In addition, Hepa/8F5 cell spheroids grown in presence of pNIPAAm after doxycycline induction
addition, Hepa/8F5 cell spheroids grown in presence of pNIPAAm after doxycycline induction
become drug-resistant, not only to tamoxifen but also to acetaminophen. This cytotoxicity study,
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become drug-resistant, not only to tamoxifen but also to acetaminophen. This cytotoxicity study,
among others, pointed out the protective role of 3D cell aggregation as a diffusion barrier to toxic
molecules [155,160,164,165]. The tight cellular 3D aggregation in spheroids brings both positive and
negative effects: on one hand, cells show improved secretive and metabolic functions; on the other
hand, the diffusional limitations inhibit molecular trafficking, which in turn has consequences on the
spheroid vitality [164].
The phenomena of cellular necrosis due to hypoxia in spheroids in some cases has been considered
a limiting factor for the use of hydrogels. However, hypoxia-induced cell death has been found in
the in vivo tumor environment in which the cells are deprived of oxygen and modify their behavior
by developing a more aggressive phenotype [166]. In an instructive study, some researchers have
developed a 3D model based on a collagen hydrogel. Co-cultures of HepG2 cells and stromal fibroblasts
have been used to obtain hetero-spheroids, namely, spheroids formed by both tumor cells and stromal
cells, of uniform and controlled size [161]. Subsequently, these were encapsulated in a collagen hydrogel
to create a 3D model of HCC also used for the evaluation of the anti-tumor drug response to DOX. The
results of this study have shown that the formation of hetero-spheroids is able to mimic some features
of the in vivo TME, in which viable, proliferating, and functionally active cells, as demonstrated by
cytochrome P450 activity, were observed.
DOX treatment showed higher chemoresistance in hetero-spheroids than in 2D culture conditions.
This phenomenon seems to be related to the compactness of the spheroid structure, in which the cells
layering on the outer surface would act as a barrier by hampering the penetration of the drug in the
innermost layers, and to the hypoxic area at the central level of the spheroid, which would modulate
the response of the cells by enhancing their endurance and vitality [155,160,161,164,165]. The increased
resistance to the DOX action has also been attributed to the presence of collagen encapsulating the
spheroids, as a further physical barrier to drug diffusion which at the same time better supports cell
vitality and proliferation thanks to cell-ECM interactions [161,164].
Xu and collaborators have used alginate hydrogels to evaluate in detail the possible cellular and
molecular mechanisms that preside over the development of HCC metastases [143]. Alginate is a
polysaccharide derived from brown algae which is widely used for its simplicity to obtain biocompatible
hydrogels [167]. The structure of these gels is obtained by ionic crosslinking with bivalent cations,
such as Ca2+ , in order to control their mechanical properties and enable a better recovery of the
spheroids [168]. In the study reported by Xu et al., two HCC cell lines, one with low metastatic
potential (MHCC97L), the other with high infiltrating capacity (HCCLM3), were encapsulated in
alginate spheres. The results highlighted that the cells grown in the spheroids reached an increased
maturity in the 3D culture with respect to the monolayers. This increase was even more evident in
the cells retaining high metastatic potential, thus suggesting that this alginate hydrogel is able to
structurally and functionally mimic the hepatic TME [143] (Figure 10). Indeed, it has been largely
reported that alginate is a valid biomaterial for long term hepatocyte cultures, including HepG2
cells [156,169]. Alginate can easily incorporate biological molecules to better mimic the liver TME
(Figure 12). Sun et al. developed decellularized liver ECM-alginate hybrid gel beads for HCCLM3 cell
culture by using a simple setup, demonstrating increased cell viability over time as a model of study for
liver cancer metastasis [170]. Concerning the dimensional control of the spheroids, Lau and coworkers
have indicated that alginate hydrogels can serve for entrapping gelatin microspheres so as to embed
HepG2 cells in a large amount [157]. After encapsulation in the hydrogel, the genipin cross-linked
microspheres were dissolved using metalloproteinase-9 (MMP-9) to create cavities with a predefined
diameter, not exceeding 200 µm, in which the cells could form small-sized spheroid aggregates. In
this way, the problem of formation of necrosis areas within the spheroidal masses due to the limits of
nutrient diffusion was better overcome [157,164]. Being a polysaccharide, alginate can be easily mixed
with other natural-origin hydro soluble biopolymers. Leung et al. have used alginate blended with
chitosan, a natural polysaccharide derived from the partial deacetylation of chitin, known to share
some structural similarities with the glycosaminoglycans present in the ECM [158].
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The use of this biomaterial combination allowed a porous and interconnected 3D structure to be
The use of this biomaterial combination allowed a porous and interconnected 3D structure to be
created, in which the characteristics of biocompatibility, biodegradation, non-immunogenicity, and
created, in which the characteristics of biocompatibility, biodegradation, non-immunogenicity, and
ability to stimulate cell differentiation were contemporaneously achieved. In particular, this study
ability to stimulate cell differentiation were contemporaneously achieved. In particular, this study
aimed to carry out a pharmacological screening by cultivating two cell lines, HepG2 and PLC/PRF/5,
aimed to carry out a pharmacological screening by cultivating two cell lines, HepG2 and PLC/PRF/5,
both on the chitosan-alginate scaffolds and 2D Matrigel®®, the latter being gelatinous protein mixture
both on the chitosan-alginate scaffolds and 2D Matrigel , the latter being gelatinous protein mixture
secreted by mouse sarcoma cells commonly used in cancer laboratory research [171]. The findings
secreted by mouse sarcoma cells commonly used in cancer laboratory research [171]. The findings
reported by these authors have highlighted the ability of this 3D models to stimulate the formation of
reported by these authors have highlighted the ability of this 3D models to stimulate the formation
cell aggregates with an increased expression of molecules related to tumor malignancy and ability
of cell aggregates with an increased expression of molecules related to tumor malignancy and ability
to metastasize. The obtained data also in this case confirmed that the 3D models enhanced cell
to metastasize. The obtained data also in this case confirmed that the 3D models enhanced cell
insusceptibility towards the chemotherapeutic drugs [158,161]. Furthermore, it was shown that the
insusceptibility towards the chemotherapeutic drugs [158,161]. Furthermore, it was shown that the
cell-hydrogel complex implanted in the animal was able to induce a strong vascularization [158].
cell-hydrogel complex implanted in the animal was able to induce a strong vascularization [158].
All the above-mentioned studies reporting on HCC spheroids obtained using hydrogels
All the above-mentioned studies reporting on HCC spheroids obtained using hydrogels
documented the improved ability of these 3D structures in recapitulating functional and chemoresistance
documented the improved ability of these 3D structures in recapitulating functional and
traits of HCC, which is poorly found if the same cells are cultured in 2D. From this point of view,
chemoresistance traits of HCC, which is poorly found if the same cells are cultured in 2D. From this
spheroids represent an easy and valuable model for HCC drug screening [158,160,161,172]. Collectively,
point of view, spheroids represent an easy and valuable model for HCC drug screening
these findings also highlighted the key role played by biomaterials, synthetic, biological, and bioartificial
[158,160,161,172]. Collectively, these findings also highlighted the key role played by biomaterials,
hydrogels in facilitating spheroid formation, size control, and cell recovery, in addition to enhancing
synthetic, biological, and bioartificial hydrogels in facilitating spheroid formation, size control, and
cell–cell and cell–matrix interactions, which in the end catalyze a more reliable cell function and drug
cell recovery, in addition to enhancing cell–cell and cell–matrix interactions, which in the end catalyze
susceptibility. In some cases, cell necrosis, frequently observable in spheroid models, can replicate
a more reliable cell function and drug susceptibility. In some cases, cell necrosis, frequently
pathological aspects and therefore be still useful in cancer research. However, the intrinsic nature of
observable in spheroid models, can replicate pathological aspects and therefore be still useful in
spheroids as artificially aggregated cell clusters is revealed by lack of morphological similarity with
cancer research. However, the intrinsic nature of spheroids as artificially aggregated cell clusters is
the native tumor, which in the end hampers more sophisticated observations to be taken from this
revealed by lack of morphological similarity with the native tumor, which in the end hampers more
3D model.
sophisticated observations to be taken from this 3D model.
7.3. Biomaterial-Based Scaffolds for HCC
7.3. Biomaterial-Based Scaffolds for HCC
The concept of cancer tissue engineering has only recently come to a diffuse scientific interest,
The concept of cancer tissue engineering has only recently come to a diffuse scientific interest,
but has attracted great attention [142,151–154]. Biomaterials-based supports endorsing the concept of
but has attracted great attention [142,151–154]. Biomaterials-based supports endorsing the concept of
tissue engineering, which relies on porous scaffolds acting as a preliminary synthetic ECM, can be
tissue engineering, which relies on porous scaffolds acting as a preliminary synthetic ECM, can be
exploited to better comprehend 3D cell behavior [173]. Conversely from spheroids, in these artificial
exploited to better comprehend 3D cell behavior [173]. Conversely from spheroids, in these artificial
microenvironments provided with porosity and topographical and mechanical cues, cells can find
microenvironments provided with porosity and topographical and mechanical cues, cells can find
their own 3D organization and hierarchical structure. The scaffolds can be provided with different
their own 3D organization and hierarchical structure. The scaffolds can be provided with different
architectures by tissue-engineers—e.g., spongy or fibrous, smooth or nanopatterned—thus resembling
architectures by tissue-engineers—e.g., spongy or fibrous, smooth or nanopatterned—thus
specific traits of a tissue of interest [149,173]. Multiple cell populations can also be seeded on these
resembling specific traits of a tissue of interest [149,173]. Multiple cell populations can also be seeded
structures, with clinically relevant dimensions (e.g., 5–8 mm size), to reach even complex macroscopic
on these structures, with clinically relevant dimensions (e.g., 5–8 mm size), to reach even complex
macroscopic 3D models [174]. Starting from early regenerative goals in the eighties, in recent years
tissue engineering has been evolving also towards in vitro tissue disease modeling, including cancer
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3D models [174]. Starting from early regenerative goals in the eighties, in recent years tissue engineering
has been evolving also towards in vitro tissue disease modeling, including cancer [142]. Only a few
review papers on cancer tissue engineering can be found before 2010, thus confirming the novelty
of this research field [152,153]. 3D scaffolds serve as an artificially created ECM able to provide a
preliminary structure for cell organization and growth, which can be highly instructive for the study of
cancer TME [142,151,153]. Indeed, both natural and synthetic origin scaffolds, provided with proper
physico-chemical, architectural, and mechanical features can provide biomimetic cues for tumor cell
growth [152,154]. Specifically, only a limited number of scaffold types have been reported, which can
give a preliminary insight on the role played by different biomaterials, mechanical properties and
structural architectures on HCC cell behavior, including, synthetic, biologic, composite (intended as
multiphase) and bioartificial (intended as synthetic and biologic blends of copolymers) [172,175–181].
As a first example, in 2007, Bokhari and collaborators have developed a 3D porous scaffold based
on polystyrene to culture HepG2 cells [172]. These authors employed a synthetic scaffold previously
developed for osteoblast growth, fabricated via high internal phase emulsion (HIPE) polymerization,
which is known as PolyHIPE Polymer (PHP). In this type of scaffold, in which the pore size and the
porosity can be tuned by changing the chemical composition of the emulsion and the processing
conditions, thus achieving maximum values of a few hundred microns and 97%, respectively [172,182].
The morphological evaluation of the HepG2/PHP constructs showed that the cells were viable, in the
proliferative phase, and were organized in aggregates enabling the formation of bile ducts rarely
observable in 2D cultures. Moreover, it was observed that the function of the cells grown on the
porous matrix was increased if compared to the monolayer culture, whereas, the 3D culture was less
susceptible to treatment with methotrexate, a hepatotoxic drug [172]. Many authors have pointed out
the need to investigate more in-depth the TME and the interactions of tumor cells with TME, in order
to clarify the molecular mechanisms underlying tumor proliferation and metastasis, with particular
emphasis to liver cancer [183].
Using the sol–gel method and leachable sucrose particles, Kataoka et al. proposed an
organic–inorganic scaffold constituted of tetraethoxysilane (TEOS) and polydimethylsiloxane
(PDMS) [176]. The authors indeed used commercial PVA scaffolds (from Able Co., Tokyo, Japan)
with pore size (130 µm and 200 µm) and porosity (about 90%) similar to those of their own scaffolds.
In TEOS–PDMS scaffolds, the HepG2 cells showed enhanced proliferation and clustering capacity with
respect to PVA scaffolds, which the authors attributed to the poral properties of PVA (e.g., smooth
pore surface and reduced size of interpore openings), supposed to impair an efficient cell clustering
in dynamic flow conditions as a consequence of the higher upstream static pressure under constant
flow, if compared to TEOS–PDMS scaffolds. As a result of 3D cultures, albumin secretion in was about
3-fold higher than in 2D cultures and independent of the scaffold polymer [176].
Among natural origin scaffolds used for liver cancer, Kundu and collaborators have reported
on silk fibers chosen for the mechanical characteristics of the material and the properties of fibroin,
a biocompatible silk protein, to naturally express the amino acid residues Arg-Gly-Asp (RGD),
as signaling molecules [177]. This amino acid sequence is present in the native extracellular collagen
and the cells are naturally able to bind it by surface integrins, showing improved viability [184]. These
scaffolds showed pores distributed in a range of 40–130 µm, values considered standard for nutrient
diffusion and cell infiltration. A particular HCC cell line was cultivated on this 3D substrate, HepR21,
which expresses at high levels the hyaluronic acid binding protein 1 (HABP1), a protein recognized
to be involved in the progression of the tumor and in the regulation of the metabolism of the tumor
cell [177]. The HepR21 cells also express high levels of hyaluronan, a component of ECM typical
of TME, which enables the formation of an extracellular reticulum, thus promoting cancerous cell
proliferation and metastasis [185]. The results of this study have proved that the HepR21 cells were
capable of adapting to the 3D support, forming aggregates evenly distributed in the scaffold and
showing a proliferative capacity and infiltration higher than the control cells (HepG2) cultivated under
the same conditions. Furthermore, the culture of these cells morphologically and functionally reflected
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the long-term culture characteristics of solid tumors in vivo [177]. Silk fibroin was blended with
chitosan, frozen and lyophilized to obtain silk fibroin/chitosan scaffolds apt for HepG2 cell growth [181].
In this system, the final porosity and mechanical properties of the scaffolds can be tuned by varying
the blend composition, thus leading to scaffolds with porosity > 95% and pores with size within
100–150 µm, if the concentration of biopolymers in the mixture is < 6% w/w. Even if this study of She
and colleagues was driven by a regenerative purpose, it was shown that HepG2 cells can intensively
proliferate in these 3D matrices, thus suggesting novel uses for their application. In another study
still aiming at liver tissue engineering, Gotoh and coworkers used silk fibroin conjugated with lactose
to obtain Lac-CY-SF sponges able to target β-galactose residues, which represent hepatocyte-specific
ligands [175]. These sponges displayed pores with variegated shape and size: round (100 µm) and
elongated (250–450 long and 100–150 µm wide). The authors compared the function of FLC-4 cells
cultured in Lac-CY-SF, plain silk fibroin and collagen sponges for 3 weeks. Interestingly, the transferrin
and HNF-4α genes were only expressed by cells cultured in Lac-CY-SF sponges. These results highlight
the specific responsiveness of cells to different biomaterial substrate and corroborate the potential of
silk as an instructive biopolymer for HCC modeling for its capability to be blended and conjugated
with other biomolecules [175,181]. In order to better mimic the liver tissue as a microenvironment
for hepatic cell growth, including HCC cells, decellularized liver appears as an interesting scaffold.
Mazza et al. were able to completely decellularize human liver with maintenance of the original
parenchymal architecture [179]. The acellular tissue was cut into 125 mm3 cubic scaffolds which were
seeded with hepatic stellate cells (LX2), hepatocellular carcinoma Sk-Hep-1 and HepG2. The cells,
cultured for 3 weeks, were vital, proliferative, and able to remodel the scaffold ECM.
The analysis of HCC TME using a tissue-engineered model has also been performed by Liang et al.,
who developed a new strategy to control the rigidity of a type of collagen hydrogel scaffold, and
minimize variations in gas permeability and the number of sites of accession [178]. In this study, a
gel was created by crosslinking collagen fibrils with various concentrations of a copolymer based on
PEG and succinic acid. The change in the mass ratio between the two polymers led to the formation of
hydrogels with variable elastic compression modules (E0 ) in the range 0.7–4.0 kPa. HepG2 cells were
embedded in these collagen-PEG supports and in pure collagen hydrogel by an on-site cross-linking
reaction. The results obtained highlighted that the tumor cells were able to form cellular aggregates
of different diameters and inversely proportional to the hydrogel rigidity. In fact, clusters with a
diameter ranging in 30–330 µm were observed in the supports in which the E0 value was 0.7 kPa
(corresponding to that of soft tissues such as fat), whereas clusters with a diameter within 20–60
µm were more represented in supports with an E0 value of 4 kPa (corresponding to that of healthy
liver) [186]. The cells of the spheroids obtained in the soft hydrogel had a proliferative and infiltration
potential much higher than those observed in the stiff hydrogel. In addition, the spheroids obtained in
soft hydrogel showed an increase in β1-integrin expression, by resulting in increased cell adhesion
to ECM, and VEGF, a factor responsible for the development of new vessels around the tumor [178].
The data obtained suggested that the rigidity of the scaffold was able to influence the phenotype and
activity of the encapsulated cells [187,188].
Among the hydrogels as 3D models of HCC have recently been studied are also those of PVA,
a synthetic polymer capable of physical cross-linking at low temperatures (i.e., cryo-gelation) by
forming lamellae that are consolidated through thermal cycles of freezing and thawing [180]. A suitable
hydrogel was obtained by adding gelatin in the PVA solution to obtain a PVA/gelatin 80/20 (w/w)
matrix with a final morphology that appeared similar to the liver parenchyma. By using bioartificial
PVA cryogels, mixed with diverse biomolecules at different weight ratios, it is possible to slightly
vary pore size distribution and scaffold inner morphology [189]. For PVA/gelatin blends, simple
freeze-thawing allowed the largest pore volume to be occupied by pores with size lower than that
obtained with emulsion and lyophilization [189–191]. Specifically, in the PVA/gelatin hydrogels
prepared by Moscato et al., 71.59% ± 5.03% of the measured volume was due to pores with diameters
ranging in 0.007–30 µm, while only 28.41% ± 4.57% of the measured volume derived from pores with
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diameters ranging in 30–150 µm [180]. Therefore, the pore size of these PVA/gelatin scaffolds greatly
differ from that of the commercial pure PVA scaffolds used by Kataoka et al., which in addition is
reported as non-distributed [176]. In PVA/gelatin hydrogels, proposed by the authors as scaffold
models for the study of HCC cell migration, HepG2 cells were cultured up to 24 days. A morphological
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As the lower pore size in this scaffold if compared to all the other ones reported in this section
possibly reduced cell motility, a better observational window of migratory phenomena was made it
possible, which could be useful for further investigations related to HCC invasiveness and progression.
Table A2 summarizes the main findings per biomaterial, model (spheroid, bead, and tissue-engineered)
and cell type (Appendix B).
The studies on biomaterials and scaffold types for HCC modeling are limited and still variegated.
Up to now, the primary applications of tissue-engineered models rely on the generation of HCC
or normal liver tissue, and no drug screening has been performed yet. Differently from spheroids,
only in tissue-engineered constructs tissue-biomimetic cellular organization has been found [172,180].
Improved cell function can be generally observed in 3D culture models, both spheroids and tissue
engineered constructs [159–161,175,176]. By applying biomaterial scaffolds as artificial ECMs, the
instructive effects of substrate compositional, physical, architectural and mechanical factors has become
evident, since in these substrates, HCC cells are able to take their own morphological and tumorigenic
nature. As a remarkable example, HeG2 showed enhanced infiltrative behavior in soft scaffolds [178].
Tissue-engineered models offer complex and fascinating TMEs for HCC understanding and also more
reliable therapeutic screening, which would offer intriguing opportunities to cancer researchers in
the future.
8. Conclusion and Future Trends
Biomaterials approaches provide versatile and easily tunable properties that can be varied to treat
and study HCC. The biomaterials span a wide range from nano to macroscale for systemic delivery,
local delivery and mimicking tumor microenvironment. The application of biomaterials may be a
promising method to repurpose existing HCC drugs that may have limited effect previously through
systemic delivery. Future development of biomaterial-based implantable devices should focus on the
local delivery of a combinational therapy instead of the delivery of one traditional method alone.
Combining chemotherapy and anti-angiogenesis may result in synergistic ability of therapies
to impeded tumor growth. Zhang et al. designed a stepwise pH-responsive NP system containing
charge reversible pullulan-based (CAPL) shell and poly(β-amino ester) (PBAE)/PLGA core to deliver
of PTX and combretastatin A4 (CA4) as a combination antiangiogenesis and chemotherapy to treat
HCC [57]. Wang et al., studying methotrexate and combretastatin A4 in pH-sensitive pullulan-based
NP carrier, enhanced antitumor and anti-angiogenic effects [91]. Future work can also focus on
applying biomaterials to capture circulating tumor cells for cancer diagnosis applications. Zhao et al.
used electrospun PVA/polyethyleneimine (PEI) nanofibers through a PEG mobilized with lactobionic
acid onto for capturing hepatocellular carcinoma cells (Figure 14) [192].
Lactobionic acid can be used to capture ASGPR overexpressing HCC cells. In conclusion,
biomaterial-based applications can deliver different bioactive factors systemically and locally and
and/or serve as tissue engineering 3D models to better understand cancer biology and find more
effective therapies for HCC. Recently, primary liver cancer-derived organoids are becoming tool for
personalized biomarker identification and drug screening, owing to their ability to reflect the genetic
complexity of the tumor [192]. It has been shown that hepatic and pancreatic cancer cells can grow in the
form of organoids (also known as tumoroids) inside ECM-based gel as a natural biomaterial [193,194].
Combination of architectural cues (e.g., topography, porosity, mechanics) provided by engineered
scaffolds and specific signaling molecules, such as those obtained from cell pre-generated ECM
or lyophilized tissues, could be integrated to generate a 3D in vitro platform enabling better HCC
understanding, thus maximizing the impact for and personalized as well as precision therapies.

of PTX and combretastatin A4 (CA4) as a combination antiangiogenesis and chemotherapy to treat
HCC [57]. Wang et al., studying methotrexate and combretastatin A4 in pH-sensitive pullulan-based
NP carrier, enhanced antitumor and anti-angiogenic effects [91]. Future work can also focus on
applying biomaterials to capture circulating tumor cells for cancer diagnosis applications. Zhao et al.
used electrospun PVA/polyethyleneimine (PEI) nanofibers through a PEG mobilized with lactobionic
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acid onto for capturing hepatocellular carcinoma cells (Figure 14) [192].

Figure 14.
SEM images of HepG2 cells captured onto (a) mPEG-PVA/PEI-Ac and (c)
LA-PEG-PVA/PEI-Ac nanofibers, respectively, after 240 min culture; (b,d) are high magnification
image of (a,c), respectively. Reprinted with permission from Royal Society of Chemistry, Zhao et al.,
RSC Advances, 2015 [191].
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Appendix A
Table A1. Biomaterials that have been investigated for drug delivery for liver cancer.
Form

Biomaterial

Bioactive Factor

Targeting Agent

Type of Therapy

Source, Year

Chemotherapy

Wang et al., 2014 [53]

Nanodiamonds
Nanodiamond

Carbon

Epirubicin
PLGA particles

Nanoparticles (NPs)

Charge reversible pullulan-based (CAPL) shell and
poly(β-amino ester) (PBAE)/poly(lactic-co-glycolic acid)
(PLGA) core

Paclitaxel (PTX) and combretastatin A4
(CA4)

Polysaccharide pullulan backbone

Anti-angiogenesis and
chemotherapy

Zhang et al., 2016 [57]

Anti-SM5-1

Chemotherapy

Ma et al., 2014 [56]

NPs

Poly d,l (lactide-coglycolide) (PLA)

5-fluorouracil (5-FU)

Microspheres

Poly(d,l-lactic-co-glycolic acid) (PLGA) core surrounded by a
poly(L-lactic acid) (PLLA) shell layer

Doxorubicin (DOX) and/or chitosan-DNA
NPs (chi-p53)

Chemotherapy and gene therapy

Xu et al., 2013 [58]

NPs

Poly(gamma-glutamic acid)-poly(lactide)

PTX

Galactosamine

Chemotherapy

Liang et al., 2006 [59]

NPs

biotin-/lactobionic acid modified poly(ethylene
glycol)-PLGA-poly(ethylene glycol) (BLPP)

Curcumin (CUR) and 5-fluorouracil (5-FU)

Biotin/lactiobionic acid

Chemotherapy/Natural therapy

Ni et al., 2018 [60]

NPs

Gelatin

DOX-lactose

Microspheres

Gelatin and chondroitin-6-sulfate

Interleukin-2

NPs

Chitosan

None

Anticancer

Qi et al., 2007 [68]

NPs

Chitosan

None

Anticancer and anti-angiogenesis

Xu et al., 2010 [67]

NPs

Chitosan

Trans-resveratrol

Biotin and avidin

Phytochemicals

Bu et al., 2013 [69]

NPs

Chitosan

Plasmid DNA with granulocyte-macrophage
colony stimulating factor, interleukin 21,
internal ribosome entry site, and retinoic
acid early transcription factor-1

Biotin

Gene therapy

Cheng et al., 2017 [70]

NPs

Galactosylated-carboxymethyl chitosan-magnetic iron oxide
(Gal-CMCS-Fe3O4)

Ras Association Domain Family 1A
(RASSF1A) gene

Galactose

Gene Delivery and Chemotherapy
(Mitomycin injected as a free drug)

Xue et al., 2016 [72,133]

NPs

Ultrasmall superparamagnetic iron oxide

SM5-1

Anti-SM51

Immunotherapy

Kou et al., 2008 [73]

NPs

Gold

miR-375

Gold

Gene therapy

Xue et al., 2016 [75]

NPs

Gold conjugated with sodium citrate or polyamidoamine
dendrimers (PAMAM)

None

Gold

Chemotherapy

Paino et al., 2012 [74]

Natural polymer-based particles
Lactose

Chemotherapy

Liu et al., 2018 [65]

Immunotherapy

Hanes et al., 2001 [66]

Metallic particles

NPs

Gold

SM5-1

Gold and selective binding of SM5-1

Immunotherapy

Ma et al., 2016 [78]

NPs

Gold with a monolayer of L-aspartate

DOX, cisplatin, capecitabine

Gold

Chemotherapy

Tomuleasa et al., 2012 [77]
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Table A1. Cont.
Form

Biomaterial

Bioactive Factor

Targeting Agent

Type of Therapy

Source, Year

Lipid-based particles
Liposomes

Soybean phosphatidylcholine/cholesterol, (PEG)ylated

DOX

Lactoferrin

Chemotherapy

Wei et al., 2015 [79]

Liposome

PEGylated liposome (liposome material unclear)

DOX

Targeting peptide SP94

Chemotherapy

Lo et al., 2008 [82]

Immuno-liposomes

1,2-dioleoyl-3-trimethylammonium-propane (chloride salt)
(DOTAP), cholesterol,
1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[maleimide
(polyethylene glycol)-2000] (DSPE-PEG-Mal),

Adriamycin (ADR) and ribonucleotide
reductase M2 (RRM2) siRNA

Anti-EGFR Fab

Chemotherapy and Gene Therapy

Gao et al., 2013 [127]

Immuno-liposomes

1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[maleimide(polyethylene
glycol)-2000] (DSPE-PEG-MAL)

DOX

Anti-CD147 antibody (Metuximab)

Chemotherapy

Wang et al., 2018 [83]

Nanomicelles

Casein

Berberine (BRB) and Diosmin (DSN)

lactobionic acid (LA) and folic acid (FA)

Phytochemicals

Abdelmoneem, 2018 [85]

Liposomal NPs

Distearoylphosphatidylcholine (DSPC), cholesterol,
dioleoylphosphatidylethanolamine (DOPE),
distearoylphosphatidylethanolamine (DSPE)-mPEG2000, and
DSPE-cyclic RGDfK

DOX or triple fusion gene for molecular
imaging

Anti-CD44 antibody

Chemotherapy

Wang et al., 2012 [84]

Gene therapy

Huang et al., 2017 [130]

Chemotherapy

Xu et al., 2009 [87]

Gene delivery

Bogorad et al., 2014 [86]

Anticancer

Wang et al., 2016 [88]

Lipid NPs

Cationic lipid RL01,
1,2-Distearoyl-sn-glycero-3-phosphatidylcholine (DSPC), and
1,2-dimyristoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy(polyethylene
glycol)-2000] (DMPE-PEG2000) and cholesterol

Lipid NPs

Trimyristin (TM), egg yolk phosphatidylcholine (ePC),
galactosylated dioleoylphosphatidyl ethanolamine (Gal-DOPE)

Docetaxel

Lipidoid

Ionizable lipid or cationic lipid, disteroylphosphatidyl choline,
cholesterol, and 1,2-dimyristoyl-sn-glycerol,
methoxypolyethylene glycol

siRNA for all integrin subunits in
hepatocytes

NPs

Hydroxyapatite

Selenium

NPs

Albumin

DOX

Galactosamine

Chemotherapy

Shen et al., 2011 [93]

NPs

N-urocanyl pullulan

Methotrexate and Combretastatin A4

Pullulan

Anti-angiogenic and chemotherapy

Wang et al., 2013 [91]

NPs

Polyisohexylcyanoacrylate (PIHCA)

DOX

Chemotherapy

Barraud et al., 2005 [94]

Dendrimer NPs

Lipids cholesterol, 1,2-distearoyl-sn-glycero-3-phosphocholine
(DSPC), and lipid PEG2000 with amine core and thiol
peripeheries

Let-7g microRNA

Gene delivery

Zhou et al., 2016 [95]

NPs

Calcium carbonate with lipid coating

Sorafenib (Sor) and miR-375

NPs

Insulin multi-methacrylate

DOX

NPs

Block copolymer PEG5k-PLA8k

SN38 prodrug

Anti-miR-17

Galactose and lactobionic acid

Other Particles

Targeting peptide, Cyclic RGD

Chemotherapy and gene therapy

Zhao et al., 2018 [92]

Chemotherapy

Bibby et al., 2005 [96]

Chemotherapy

Wang et al., 2018 [61]

Local Delivery
Nanofibers NPs
(immobilized on the
nanofibers)

Poly(ε-caprolactone) disulfide cross linked branched PEI
(ssPEI)

PTX and miRNA-145

Chemotherapy and gene delivery

Che et al., 2015 [98]

Microspheres

Glass

Phosphorus-32

Radiotherapy

Wang et al., 2008 [97]
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Table A1. Cont.
Form

Biomaterial

Bioactive Factor

Targeting Agent

Type of Therapy

Source, Year

Polymer millirods

Poly(lactic-co-glycolic acid) PLGA

DOX
carboplatin
5-fluorouracil

Chemotherapy

Qian et al., 2002 & 2004
[101,103]
Szymanski-Exner et al.,
2003 [102]; Weinberg et al.,
2007 & 2007 [99,100]

Drug eluting beads

Sulfonate-modified poly(vinyl alcohol) hydrogel

DOX
sor

TACE, chemotherapy

Pawlik et al., 2011 [109]

Drug-eluting
microspheres/beads
(DEB)

Sulfonate-modified poly(vinyl alcohol) hydrogel

DOX

TACE, chemotherapy

Hong et al., 2006 [108]

Drug eluting beads

Polyvinyl alcohol polymer modified with sulfonate groups to
form a hyodrogel

DOX

TACE, chemotherapy

Poon et al., 2007 [111]

Microspheres

Poly-lactide-co-glycolide PLGA

Mitomycin

TACE, chemotherapy

Qian et al., 2003 [110]

Cancer diagnosis

Zhao et al., 2015 [191]

Biomaterials to capture cells
Nanofibers

Lactobionic acid-functionalized electrospun polyvinyl
alcohol/polyethyleneimine via PEG spacer

Diagnostic purposes
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Appendix B
Table A2. Biomaterials that have been investigated for 3D models for studying liver cancer.
Biomaterial

Type

Model

Cells

Application

Results

Source, Year

PEG (8-arm PEG-SH)

Spheroid

HepG2

Spheroid formation and recovery due to
polymer biodegradation with cysteine

Increased cell function (albumin and urea)

Moriyama et al., 2016 [159]

TME bio-mimicry: bile duct formation and higher drug resistance

Bokhari et al., 2007 [172]

Synthetic

Polystyrene (PHP)

Tissue Engineered (TE)

HepG2

Structure, function and cytotoxicity
study (methotrexate)

TEOS–PDMS

TE

HepG2

Function under dynamic flow

TME bio-mimicry: increased proliferation and aggregation capacity,
higher albumin synthesis than in 2D cultures

Kataoka et al., 2005 [176]

PVA

TE

HepG2

Function under dynamic flow

TME bio-mimicry: higher albumin synthesis than in 2D cultures

Kataoka et al., 2005 [176]

Collagen

Hetero-spheroid

HepG2 and stromal
fibroblasts

Cytotoxicity study (DOX)

TME bio-mimicry: cell function (P450 activity) and increased
drug resistance

Yip et al., 2013 [161]

Alginate

Spheroid

MHCC97L HCCLM3

Metastatic mechanism study

TME bio-mimicry: increased cell maturity, in particular in metastatic
cells MHCC97L

Xu et al., 2013 [143]

Alginate/chitosan
blend

Spheroid

PLC/PRF/5 HepG2

Cytotoxicity study (DOX)

TME bio-mimicry: increased malignancy and drug resistance

Leung et al., 2010 [158]
Kundu et al., 2013 [177]

Biologic

Silk fibroin

TE

HepR21 HepG2

TME study

HepR21 showed irregular aggregation and higher proliferation capacity
than HepG2

Silk fibroin/chitosan

TE

HepG2

Liver regeneration

Mechanical properties controllable, good cell proliferation

She et al., 2008 [181]

Silk fibroin-lactose
(Lac-CY-SF)

TE

FALC-4

Liver regeneration

Functional gene expression not found using collagen

Gotoh et al., 2011 [175]

Decellularized human
liver tissue

TE

LX2
Sk-Hep-1
HepG2

Liver regeneration

Bio-compatibility and ECM remodeling

Mazza et al., 2015 [179]

Alginate/decellularized
liver ECM

Bead

HCCLM3

Metastatic mechanism study

TME bio-mimicry: Increased cell viability and metastatic potential due to
liver ECM

Sun et al., 2018 [170]

Alginate/gelatin
microspheres

Spheroid

HepG2

Formation of spheroids with defined size
by microsphere dissolution with MMP-9

Spheroids of 200 µm with no necrotic core

Lau et al., 2012 [157]

pNIPAAm-co-gelatin

Spheroid

Hepa/8F5

Cytotoxicity study
(tamoxifen and acetaminophen)

Increased cell function (albumin CYP3A4 activity, ammonia removal) and
drug resistance

Sarkar et al., 2017 [160]

Collagen-PEG/succinic
acid

TE

HepG2

Effect of material stiffness

Higher cell cluster size and infiltration capacity in softer hydrogels

Liang et al., 2011 [178]

PVA/gelatin

TE

HepG2

Cell migration

TME bio-mimicry: tissue-like cell organization, possibility to visualize
migratory phenomena

Moscato et al., 2015 [180]

Composite

Bioartificial
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